Brainomix has expanded its Series C round to £18.8m to scale its AI stroke and lung imaging platforms, with a focus on accelerating deployment in the US.
The company added £4.8m to fund growth of its two core products. Brainomix 360 Stroke automates imaging assessment across the acute stroke pathway to support treatment and patient transfer decisions.
E-Lung uses CT-based biomarkers, measurable imaging signals, to detect, monitor and predict the progression of fibrosing lung disease, where scarring of lung tissue worsens over time.
With an established footprint in the US and multiple AI solutions cleared by the US Food and Drug Administration, Brainomix said it will invest the new capital in faster rollout, deeper customer support and smoother integration of its technology into clinical workflows in the US and Europe.
The company operates in more than 20 countries.
Dr Michalis Papadakis, chief executive and co-founder of Brainomix, said the funding underlines investor confidence in the platform and its role in speeding stroke care and enabling earlier, more consistent decision-making in lung fibrosis.
The extension was led by existing backers Parkwalk Advisors and Hostplus through the IP Group Hostplus Innovation Fund, and joined by new US investor Modi Ventures. Modi Ventures highlighted clinical data suggesting Brainomix 360 Stroke can increase rates of endovascular thrombectomy, a procedure to remove blood clots from the brain, and reduce triage and transfer delays, particularly in primary stroke centres.
